Cancer is not a standalone disease; it often intersects with other chronic conditions, creating complex medical challenges. The co-occurrence of cancer and diseases such as diabetes, cardiovascular conditions, and autoimmune disorders can significantly impact diagnosis, treatment, and outcomes. For example, patients with diabetes may experience altered cancer progression or treatment side effects due to insulin resistance. Similarly, cardiovascular diseases can complicate cancer treatments that affect heart function, necessitating careful management. Research in cancer's intersection with other diseases is crucial to developing integrated treatment approaches that address multiple health concerns simultaneously. This growing area of study aims to enhance personalized medicine, offering patients more effective, tailored therapies that take into account the interplay between cancer and co-existing conditions. Such research is pivotal in improving survival rates and quality of life for patients navigating these multifaceted health challenges.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China